Spondyloarthritis & psoriatic arthritis
Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network
Authors' conclusion
This is the first nationwide study that we know of to describe real-world use of SEC in Canada for PsA, and the results support its effectiveness in a Canadian real-world setting.
Study context
- Population
- Canadian patients with psoriatic arthritis (PsA), 18 to 65 years, attending a Canadian Spondyloarthritis (CanSpA) network clinic and treated with secukinumab (SEC)
- Participants
- 213 patients
- Outcome
- Retention of SEC
- Follow-up
- 12 months postindex
Methodological detailsreal-world, multicentre (CanSpA network)
- Real-world
- Multicentre (CanSpA network)
Main finding
As reported in the abstract
Overall retention · 12 months
Overall retention
73.6%
Observational data: associations, not effects.
Further findings
Retention, biologic disease-modifying antirheumatic drug (bDMARD)- or tsDMARD-naïve (subgroup) · 12 months
- Retention in bDMARD- or tsDMARD-naïve
- 81.8%
Remission by DAPSA28 · 12 months
- In remission (DAPSA28), 17 of 110
- 15.5%
Remission by PASDAS · 12 months
- In remission (PASDAS), 10 of 70
- 14.3%
PASI improvement
- PASI improved
- 65.8%
Tender joint count (68) and swollen joint count (66) improvement
- Tender joint count (68 joints) improved
- 65.5%
- Swollen joint count (66 joints) improved
- 73.7%
Original publication
Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network. J Rheumatol. Published 15 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →